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Signaling through the apelin receptor is beneficial for a number of diseases including
pulmonary arterial hypertension. The endogenous small peptides, apelin and elabela/
toddler, are downregulated in pulmonary arterial hypertension but are not suitable for
exogenous administration owing to a lack of bioavailability, proteolytic instability and
susceptibility to renal clearance. CMF-019, a small molecule apelin agonist that displays
strong bias towards G protein signaling over β-arrestin (∼400 fold), may be more suitable.
This study demonstrates that in addition to being a positive inotrope, CMF-019 caused
dose-dependent vasodilatation in vivo (50 nmol 4.16 ± 1.18 mmHg, **p < 0.01; 500 nmol
6.62 ± 1.85 mmHg, **p < 0.01), without receptor desensitization. Furthermore, CMF-019
rescues human pulmonary artery endothelial cells from apoptosis induced by tumor
necrosis factor α and cycloheximide (5.66 ± 0.97%, **p < 0.01) by approximately 50%
of that observable with rhVEGF (11.59 ± 1.85%, **p < 0.01), suggesting it has disease-
modifying potential in vitro. CMF-019 displays remarkable bias at the apelin receptor for a
small molecule and importantly recapitulates all aspects of the cardiovascular responses to
the endogenous ligand, [Pyr1]apelin-13, in vivo. Additionally, it is able to protect human
pulmonary artery endothelial cells from apoptosis, suggesting that the beneficial effects
observed with apelin agonists extend beyond hemodynamic alleviation and address
disease etiology itself. These findings support CMF-019 as a G protein biased small
molecule apelin agonist in vitro and in vivo that could form the basis for the design of novel
therapeutic agents in chronic diseases, such as, pulmonary arterial hypertension.
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INTRODUCTION
The apelin receptor, a class A G protein coupled receptor
(O’Dowd et al., 1993) has two endogenous peptide ligands,
apelin (Tatemoto et al., 1998) and elabela/toddler (ELA)
(Chng et al., 2013; Pauli et al., 2014). The apelin system is a
therapeutic target in diseases (Read et al., 2019), such as diabetes
(Castan-Laurell et al., 2012), fibrosis (Huang et al., 2016), heart
failure (Berry et al., 2004; Jia et al., 2006; Atluri et al., 2007;
Koguchi et al., 2012; Pang et al., 2014) and pulmonary arterial
hypertension (PAH) (Falcão-Pires et al., 2009; Yang et al., 2015).
In PAH, apelin (Goetze et al., 2006; Alastalo et al., 2011; Kim
et al., 2013) and ELA (Yang et al., 2017) are downregulated but
receptor expression is maintained (Andersen et al., 2009; Falcão-
Pires et al., 2009) therefore replacing the missing ligands could be
a therapeutic strategy. In a model of PAH [Pyr1]apelin-13
(Falcão-Pires et al., 2009; Maguire et al., 2009) and ELA-32
(Yang et al., 2017) prevented disease onset, however, both lack
oral bioavailability and are susceptible to proteolytic cleavage and
renal excretion. Furthermore, repeated agonist stimulation leads
to β-arrestin recruitment and receptor internalization, potentially
blunting therapeutic efficacy.
A preferable strategy is to identify G protein biased apelin
ligands (Brame et al., 2015). We have identified a small
molecule, CMF-019 (Hachtel, et al., 2014), that is a positive
inotrope in vivo and possesses strong G protein bias. CMF-019
has nanomolar affinity for the apelin receptor in both human
and rat heart and whereas this compound inhibits Gαi mediated
cAMP accumulation with sub-nanomolar potency comparable
to [Pyr1]apelin-13 it is over two orders of magnitude less
efficient in recruiting β-arrestin or inducing apelin receptor
internalization compared to the endogenous agonist (Read et al.,
2016). In this study we have investigated whether CMF-019
alters apoptosis in human pulmonary arterial endothelial cells
(PAECs), a driver of early disease phase (Wilson et al., 1992;
Rabinovitch 2012). We aimed to confirm that a G protein biased
compound produces vasodilatation in vivo, (the main
mechanism of action for most current PAH therapies)
without desensitization, as recent studies have suggested that
apelin-mediated vasodilatation may occur via β-arrestin
signaling (El Messari et al., 2004; Iturrioz et al., 2010;
Ceraudo et al., 2014).
MATERIALS AND METHODS
Materials
Chemicals were obtained from Sigma Aldrich Co. Ltd. (Poole,
United Kingdom) unless otherwise stated [Pyr1]apelin-13 (purity
>98%) was from Severn Biotech (Kidderminster,
United Kingdom). CMF-019 was synthesized as a potassium
salt (Read et al., 2016), initially in the School of Chemistry,
University of Leeds (purity > 95%) and later by Tocris (purity
99.3%) (Bristol, United Kingdom). All animal care and rodent
experiments complied with the Home Office (United Kingdom)
guidelines under the Animals (Scientific Procedures) Act 1986
Amendment Regulations (SI 2012/3,039) and were approved by
the local ethics committee (University of Cambridge Animal
Welfare and Ethical Review Body).
Rescue of Human Pulmonary Artery
Endothelial Cell Apoptosis
The effects of CMF-019 on endothelial cell apoptosis were tested
and compared with recombinant human vascular endothelial
growth factor (rhVEGF; R&D Systems, Minneapolis, MN,
United States) using human PAECs (Lonza; Cambridge,
United Kingdom; n  5 donors: 1 (lot#0000479486), 2
(lot#4F3041), 3 (lot#4F3034), 4 (lot#000657513) and 5
(lot#0000662151), passages 4–6) as previously described (Long
et al., 2015) following protocol optimization. Briefly, PAECs were
seeded in six-well tissue culture plates at 200,000 cells/well in
endothelial growth medium-2 (EGM-2; Lonza, PromoCell;
United Kingdom) with 10% fetal bovine serum (FBS, Gibco™,
NY, United States) and allowed to attach. On the next day, wells
were washed with PBS and the media changed to either
endothelial basal medium 2 (EBM-2; Lonza, PromoCell) with
2% FBS or 10% FBS controls. CMF-019 (1–10 µM) or rhVEGF
(10 ng/ml) were added to the wells and incubated for 18 h.
Apoptosis was induced by incubating the cells with tumor
necrosis factor α (TNFα; R&D Systems, 1.5 ng/ml) and
cycloheximide (CHX; 20 μg/ml) for 5 h in the experimental
wells. Control wells did not receive TNFα/CHX treatment.
Cells were then washed in PBS, trypsinized (Lonza),
transferred into 1x binding buffer for the apoptosis assay
(Thermoscientific; Waltham, MA, United States) and stained
with anti-annexin FITC-conjugated antibody (1:2 stock
dilution) and propidium iodide (PI, 20 μg/ml) for 15 mins at
room temperature. Cells were filtered through 50 µM filters
(Sysmex/Partec; Görlitz, Germany) and kept on ice before flow
cytometry (Canto II, BD Biosciences; San Jose, CA,
United States). For each condition 10,000 events were
recorded. Data analysis was performed on FlowJo v10 (FlowJo
LLC; Ashland, OR, United States). Annexin+/PI+ cells were
classified as “dead,” Annexin+/PI− cells “apoptotic” and
Annexin−/PI− as “healthy.” Gates were adjusted such that
approximately equal numbers of “healthy” and “apoptotic”
cells occurred in the TNFα/CHX treated group as this
provided a large window for either further induction or rescue
of apoptosis. The raw percentage of cells in each gate were used in
the data analysis and some variability in the basal amount of
apoptotic induction between replicates was observed. A matched
ANOVA was utilized to remove this variability and compare data
trends.
In vivo Catheterization to Assess
Cardiovascular Responses to CMF-019 in
Normotensive Male Sprague-Dawley Rats
Normotensive male Sprague-Dawley rats (271 ± 3 g, n  17)
underwent left ventricular and femoral artery catheterization to
assess cardiac and vascular changes upon bolus CMF-019
administration. Left ventricular catheterization was performed
as previously described (Pacher et al., 2008; Read et al., 2016;
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Yang et al., 2017) and the femoral catheterization protocol was
developed as an extension to this protocol. In brief, rats were
anaesthetized with gaseous isoflurane (3–2.5% for initial
induction, maintenance and surgery, and 1.5% for
hemodynamics measurement; 1.5 L/min oxygen). The right
external jugular vein was exposed, cannulated and flushed
with heparin solution (2%) made up in saline (0.9% saline,
pH5, Macopharma; Tourcoing, FR). The right common
carotid artery was then located and a catheter (SPR-869,
Millar Inc.; Houston, TX, United States) inserted and
advanced to the left ventricle. Once a stable pressure-volume
loop could be observed, the femoral artery was exposed and a
second identical catheter inserted to record arterial pressure
responses simultaneously to the ventricular responses. Three
successive doses of either CMF-019 (50–5000 nmol, 0.5 ml,
0.9% saline, pH9), [Pyr1]apelin-13 (10–150 nmol, 0.5 ml, 0.9%
saline, pH5) or saline controls were then administered
intravenously via the jugular vein catheter, followed by a
saline flush (0.9%, 0.1 ml, pH5) at a minimum of 10 mins
intervals or when a stable baseline was reached before the next
injection. All animals received a 50 nmol dose of [Pyr1]apelin-13
as a fourth dose after they had received their first three
doses whether they be saline, CMF-019 or [Pyr1]apelin-13.
The dosing schedule is summarized in Figure 1. Data were
acquired using the MPVS Ultra system (ADIstruments;
Dunedin, NZ) and analyzed using LabChart 8
(ADIstruments). Values for the maximal change in arterial
pressure, left ventricular systolic pressure (LVSP), stroke
volume, cardiac output, heart rate, contractility (dP/dtMAX)
and lusitropy (dP/dtMIN) from baseline were calculated from
the raw data and compared. Following completion of the
measurements the animal was euthanized by exsanguination
under high flow isoflurane (5%).
Statistical Analysis
All data are expressed as mean ± SEM values and statistical
analyses were performed with GraphPad Prism 6 (La Jolla, CA,
United States) unless otherwise stated. For rescue of human
PAEC apoptosis, experiments were performed at least in
triplicate. Donors four and five were excluded from the
analysis as they showed a particularly small window of
apoptotic cell induction using TNF-α and CHX (2.80 ±
1.60%), this was not significantly different to the EBM-2 2%
FBS control (Matched ANOVA). Of the remaining donors,
technical replicates were excluded if the apoptotic induction
was less than 5%. The average induction of apoptosis of the
analyzed experiments was 19.53 ± 1.76%. Data were normally
distributed using a D’Agostino-Pearson omnibus K2 test and
trends were compared using a matched ANOVA to account for
variability observed in the basal amount of apoptotic induction
observed between replicates. For the acute in vivo studies,
normality has been confirmed by analyzing data collected over
a number of experiments using the D’Agostino-Pearson omnibus
K2 test. Consequently, cardiovascular parameters measured in
saline were compared to CMF-019 and [Pyr1]apelin-13 treated
animals using a two-tailed Student’s t-test. Statistical significance
was taken as 5%.
RESULTS
CMF-019 Rescued Human PAEC Apoptosis
Induced by TNFα and CHX
The ability of CMF-019 to prevent TNFα/CHX induced apoptosis
in human PAECs was tested at 1 and 10 µM (Figures 2, 3). TNFα/
CHX significantly increased the percentage of annexin+/PI− cells
(19.54 ± 1.76%, ####p < 0.0001) compared to the EBM-2 2% FBS
control and rhVEGF was able to partially rescue this (11.59 ±
1.85%, **p < 0.01), as was CMF-019 at 1 µM (5.66 ± 0.97%,
**p < 0.01). CMF-019 at 10 µM displayed no significant rescue
despite trending towards significance (4.38 ± 1.48%, ns)
(Figure 3).
In control experiments assessing apoptotic responses and
rescue to growth factor and serum starvation (Figure 4),
growth factor and serum starvation significantly increased the
percentage of annexin+/PI− cells (9.33 ± 1.94%, ##p < 0.01)
compared to the EGM-2 10% FBS “healthy” control and
rhVEGF was able to completely rescue this (8.86 ± 1.07%,
***p < 0.001). However, CMF-019 at 1 µM (1.04 ± 0.86%, ns)
and 10 µM (−0.91 ± 0.86%, ns) displayed no rescue in these
conditions.
FIGURE 1 | Dosing schedule for the second in vivo study. The left ventricle and femoral artery were catheterized in normotensive male Sprague-Dawley rats.
Subsequently, the animals were randomly chosen to receive either three doses of saline, CMF-019 or [Pyr1]apelin-13, before a fourth dose of 50 nmol [Pyr1]apelin-13
was administered regardless of the previous doses administered. Doses were administered at 10 mins intervals or when a stable baseline was reached after which the
animal was terminated by exsanguination under high flow isoflurane.
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CMF-019, a G Protein Biased Small
Molecule, Reduced Peripheral Artery
Pressure In Vivo
Measured by catheterization of the femoral artery, bolus CMF-
019 administration via the jugular vein revealed reproducible
peripheral reduction in femoral artery pressure compared to
saline at 50 nmol (4.16 ± 1.18 mmHg, **p < 0.01) and
500 nmol (6.62 ± 1.85 mmHg, **p < 0.01) (Figure 5A). At the
highest dose of 5000 nmol the response was not significant. [Pyr1]
apelin-13 produced a larger dose dependent decrease in blood
pressure at all doses administered (10 nmol 12.06 ± 3.51 mmHg,
*p < 0.05; 50 nmol 31.24 ± 8.70 mmHg, **p < 0.01 and 150 nmol
31.75 ± 9.53 mmHg, *p < 0.05) (Figure 5B).
Cardiac Responses In Vivo to CMF-019 and
[Pyr1]Apelin-13
CMF-019 increased cardiac contractility (500 nmol 251 ±
89 mmHg/s, *p < 0.05), stroke volume (50 nmol 2.63 ±
0.82 RVU, **p < 0.01; 500 nmol 2.48 ± 0.87 RVU, *p < 0.05),
cardiac output (50 nmol 1,097 ± 284 RVU/min, **p < 0.01;
500 nmol 1,012 ± 340 RVU/min, *p < 0.05) and produced a
small elevation in heart rate (500 nmol 5.46 ± 2.32 BPM, *p <
0.05) (Figure 6). CMF-019 decreased LVSP (50 nmol 1.88 ±
0.57 mmHg, **p < 0.01; 500 nmol 2.23 ± 0.80 mmHg, *p <
0.05) in concert with the arterial pressure. A very small
decrease in lusitropy was also observed (50 nmol 210 ±
70 mmHg/s, *p < 0.05). Similar to CMF-019, [Pyr1]apelin-13
increased cardiac contractility (150 nmol 1920 ± 178 mmHg/s,
***p < 0.001), stroke volume (10 nmol 4.72 ± 0.98RVU, **p <
0.01; 50 nmol 9.70 ± 1.93RVU, **p < 0.01; 150 nmol 9.84 ±
3.02 RVU, *p < 0.05), cardiac output (10 nmol 2,008 ±
464 RVU/min, **p < 0.01; 50 nmol 3,618 ± 818 RVU/min,
**p < 0.01; 150 nmol 3,961 ± 1154 RVU/min, *p < 0.05) and
decreased LVSP (10 nmol 5.66 ± 0.81 mmHg, ***p < 0.001;
50 nmol 11.02 ± 1.70 mmHg, ***p < 0.001; 150 nmol 9.47 ±
1.16 mmHg, ****p < 0.0001). [Pyr1]apelin-13 produced a small
elevation in heart rate (150 nmol 12.94 ± 4.95 BPM, *p < 0.05)
and a small decrease in lusitropy was observed (150 nmol 1,143 ±
378 mmHg/s, *p < 0.05) which was consistent with CMF-019
(Figure 6). The time course for the effect of both compounds was
similar. No adverse effects were observed at any of the doses
administrated.
FIGURE 2 | Representative contour plot flow data of human PAECs induced to apoptosis with TNFα/CHX and rescued with either rhVEGF or CMF-019 at 1 µM.
Cells were incubated in EGM-2 with 10% FBS (control); EGM-2 with 2% FBS and TNFα/CHX (TNFα/CHX) treatment for 5hrs to induce apoptosis before rhVEGF (10 ng/
ml) or CMF-019 (1–10 μM) was added for a further 18 h. PI staining is displayed on the x-axis and annexin-V FITC staining on the y-axis. The percentage of cells in each
quadrant are shown in the corners of the quadrant.
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CMF-019 Did Not Desensitize the Apelin
Receptor In Vivo
To study desensitization at the apelin receptor in vivo, a fourth
dose of [Pyr1]apelin-13 at 50 nmol was administered to the saline,
CMF-019 and [Pyr1]apelin-13 treatment groups (Figure 7). The
x-axis denotes whether the preceding three doses were either
saline or increasing doses of CMF-019 or [Pyr1]apelin-13. The
responses to [Pyr1]apelin-13 in CMF-019 treated animals
compared to saline treated animals were not significantly
different for any parameter indicating that CMF-019 did not
significantly desensitize the receptor compared to saline. In
contrast there was a trend for the response to 50 nM [Pyr1]
apelin-13 to be blunted in for all parameters following the three
successive [Pyr1]apelin-13 doses that reached significance for the
contractility response (p < 0.001) consistent with desensitization.
DISCUSSION
CMF-019 Modified Disease in a Human
PAEC Apoptotic Model
In the advanced stages of PAH, pathological remodeling of
pulmonary vessels occurs including endothelial proliferation
and the development of distinctive plexiform lesions which
may in part be driven by imbalances in apelin signaling
(Andersen et al., 2011; Yang et al., 2015). However, in early
disease it is thought that endothelial cell apoptosis, leading to
vascular dysfunction may drive onset (Wilson et al., 1992; Sakao
et al., 2005; Rabinovitch, 2012). Apelin has been suggested to
mitigate these effects and promotes survival of pulmonary
vascular endothelial cells (Alastalo et al., 2011; Kim et al.,
2013). Here we have studied the ability of the G protein
biased small molecule apelin agonist, CMF-019, to promote
human PAEC survival in response to apoptotic stimulation
with TNFα/CHX. TNFα may prevent apoptosis of endothelial
cells through activation of the NF-κB pathway, however, in
conditions of global protein synthesis suppression, such as,
with concurrent application of CHX, signaling through TNF-
R1 dominates leading to JNK phosphorylation and induction of
apoptosis (Wajant et al., 2003).
Both CMF-019 and rhVEGF rescued endothelial cells from
TNFα/CHX induced apoptosis. The rescue with CMF-019 was
approximately 50% of that observed for the positive control,
rhVEGF, and supports a role for apelin agonists in preventing
endothelial damage in healthy human PAECs when challenged
with an apoptotic stimulus. The mechanism by which this occurs
is not well characterized, however, both [Pyr1]apelin-13 and
ELA-32, endogenous agonists of the apelin receptor (Read
et al., 2019), promote ERK1/2 phosphorylation in human
PAECs (Yang et al., 2017), while some apelin isoforms have
been shown to downregulate the JNK and p-38 pathways in
osteoblasts (Tang et al., 2007) and neurons (Liu et al., 2018).
These pathways both have known roles in apoptosis.
Furthermore, there is evidence that apelin regulates myocyte
enhancer factor 2, which in turn can activate miR-424/miR-
503 and genes contributing to endothelial cell homeostasis.
This axis may also be beneficial in PAH by acting on
pulmonary arterial smooth muscle cells. Here it inhibits the
expression of fibroblast growth factor 2 and its receptor, and
thus, exerts anti-proliferative effects, potentially preventing their
over-proliferation and subsequent vessel muscularization
FIGURE 3 | Dot plot of the percentage of annexin+/PI− human PAECs in
each experimental condition withmean ± SEMdata superimposed. Cells were
incubated in EGM-2 with 2% FBS alone (control) or EGM-2 with 2% FBS and
treated with TNFα/CHX (TNFα/CHX) for 5hrs to induce apoptosis before
rhVEGF (10 ng/ml), or CMF-019 (1–10 μM) was added to TNFα/CHX treated
cells for a further18hrs. TNFα/CHX significantly increased the percentage of
annexin+/PI− human PAECs and this could be rescued by 10 ng/ml rhVEGF
and CMF-019 at 1 µM. Matched ANOVA comparing each condition to TNFα/
CHX **p < 0.01. #### indicates p < 0.0001 compared to control (EBM-2
2% FBS).
FIGURE 4 | Dot plot of the percentage of annexin+/PI− human PAECs in
each experimental condition withmean ± SEMdata superimposed. Cells were
incubated in EGM-2 with 10% FBS alone (“growth factor control”), EGM-2
with 2% FBS alone (serum starvation) or EGM-2 with 2% FBS and 18hrs
treatment with rhVEGF (10 ng/ml) or CMF-019 (1–10 μM). Growth factor and
serum starvation (EBM-2 2% FBS) significantly increased the percentage of
annexin+/PI− human PAECs and this could be rescued by 10 ng/ml rhVEGF.
CMF-019 did not rescue. Matched ANOVA comparing each condition to the
EBM-2 2% FBS condition ***p < 0.001. ## indicates p < 0.01 compared to the
“healthy” control (EGM-2 10% FBS).
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(Alastalo et al., 2011; Kim et al., 2013; Helenius et al., 2015; Kim
et al., 2015). Finally, agents that activate apelin expression or act
as downstream effectors of apelin signaling have demonstrated
beneficial effects in PAH animal models (Kim et al., 2013;
Spiekerkoetter et al., 2013; Bertero et al., 2014; Nickel et al., 2015).
Interestingly, CMF-019 did not rescue apoptosis induced by
serum and growth factor starvation in the control arm of the
experiment, although the positive control rhVEGF did. This
suggests that rescue from serum and growth factor starvation
is through a different mechanism to rescue from TNFα/CHX
induced apoptosis. Growth factor and serum starvation has been
widely observed in various endothelial cell lines (Karsan et al.,
1997; Gerber et al., 1998b; Raymond et al., 2004; Date et al., 2005;
Ueda et al., 2005; Gama Sosa et al., 2016) and the mechanisms for
rescue with rhVEGF are thought to occur by both upregulation of
the MAPK/ERK pathway alongside downregulation of JNK
pathway (Gupta et al., 1999), leading to enhanced bcl-2 and
decreased bax signaling (Karsan et al., 1997; Gerber et al., 1998a;
Ueda et al., 2005). In contrast, TNFα/CHX stimulates apoptosis
primarily through the TNF-R1 leading to induction of the JNK
and p-38 MAPK pathways. On balance there is greater evidence
of apelin promoting ERK/MAPK signaling, especially in PAECs,
and perhaps activation of this pathway was more efficacious in
rescuing from JNK/p-38 mediated apoptosis induced by TNFα/
CHX, rather than the multiple pathway mechanisms of apoptosis
induced by serum and GF starvation.
This fact that CMF-019 rescued only in the TNFα/CHX
condition may suggest it as a potential disease modifier in
that it prevented endothelial cell apoptosis in conditions of a
severe stimulus but did not have an effect in response to the
weaker serum and GF starvation stimulus. Similar results were
observed with the cyclic peptide, MM07, also a G protein biased
apelin agonist which was effective in preventing PAH onset in a
rat MCT model, suggesting a potential mechanism for
modification of disease onset (Yang et al., 2019). Although
[Pyr1]apelin-13 was administered in similar cell apoptosis
experiments (data not shown), no rescue was observed and
this was thought to be due either to proteolytic breakdown or
high plasma protein binding in serum over the prolonged 18 h
incubation time. Protease inhibitors cannot be used in this assay
to prevent apelin breakdown as these would confound it by
negating protein synthesis inhibition by CHX (unpublished
observation).
CMF-019 Reduced Peripheral Artery
Pressure and Increased Cardiac Output
In vivo
CMF-019 administered by bolus intravenous injection through a
jugular vein cannula in normotensive male Sprague-Dawley rats
induced both a reduction in pressure recorded in the femoral artery
and cardiac responses, as did [Pyr1]apelin-13. Consistent with
cardiac responses that we have previously reported to CMF-019
and [Pyr1]apelin-13 (Read et al., 2016), in this study both apelin
agonists displayed reproducible enhancement of contractility,
stroke volume and cardiac output. The maximum response to
CMF-019 was smaller than that observed for [Pyr1]apelin-13 and
this was likely due to the limited concentrations of CMF-019 that
could be attained in vivo as previously stated. In our previous
report CMF-019 had little effect on LVSPwith a small increase seen
at the highest dose. We postulated that the lack of effect of CMF-
019 may be explained either by limited solubility or that
vasodilatation resulting from apelin receptor activation may be
a β-arrestin mediated response. We therefore extended the
protocol in this study to also measure pressure changes in the
femoral artery. In the current study we observed a small decrease in
LVSP with CMF-019 consistent with the larger decreases obtained
with [Pyr1]apelin-13. Crucially, CMF-019 induced a reduction in
femoral artery pressure following administration which has not
been previously demonstrated. This response most likely reflects a
decrease in peripheral resistance, consistent with CMF-019, like
[Pyr1]apelin-13, acting as vasodilators, as both molecules increase
stroke volume. It has been suggested that longer apelin peptides,
such as apelin-17, display β-arrestin bias by reaching deeper within
the apelin binding pocket and through these contacts they both
internalize the receptor and signal to produce vasodilatation (El
Messari et al., 2004; Iturrioz et al., 2010; Ceraudo et al., 2014). This
theory for β-arrestin bias seems likely and we observe that smaller
and cyclic peptides, such as MM07, possess G protein bias, while
the small molecule CMF-019 displays the greatest G protein bias
we have observed (Read et al., 2016). However, from our results
this does not correlate with a reduced ability to produce
FIGURE 5 | The arterial pressure change in response to CMF-019 and [Pyr1]apelin-13 in vivo.Decreases in arterial pressure in anaesthetizedmale Sprague-Dawley
rats to (A) intravenous CMF-019 potassium salt (■, n  8) and (B) [Pyr1]apelin-13 (apelin,▲, n  5) compared to saline (C, n  4) control. Each dose was compared by a
Student’s t-test to its corresponding saline control as doses were administered cumulatively (*p < 0.05, **p < 0.01).
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FIGURE 6 | Cardiovascular responses to CMF-019 and [Pyr1]apelin-13 in vivo. Graphs showing changes in contractility (dP/dtMAX; A–B) left ventricular systolic
pressure (LVSP; C–D), stroke volume (SV; E–F), cardiac output (CO; G–H), heart rate (HR; I–J) and relaxation (dP/dtMIN; K-L) for CMF-019 potassium salt (■, n  8, A
andC, E, G, I, K) and [Pyr1]apelin-13 (apelin,▲, n  5,B, D, F, H, J, L) compared to saline (C, n  4,A–H) when injected intravenously into anaesthetizedmale Sprague-
Dawley rats. Each dose was compared by a Student’s t-test to its corresponding saline control as doses were administered cumulatively (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001).
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vasodilatation. In fact, given the marked bias of CMF-019 towards
the G protein pathway, it suggests that vasodilatation is possible
without engagement of β-arrestin signaling and receptor
internalization. This is further supported by the sustained
vasodilatation observed in humans in vivo with MM07 (Brame
et al., 2015).
CMF-019 Did Not Desensitize the Apelin
Receptor In Vivo
It has previously been shown that CMF-019 displays weak activity
in recruiting β-arrestin and internalizing the apelin receptor
in vitro (Read et al., 2016). Therefore, to assess the ability of
CMF-019 to internalize the apelin receptor in vivo, a protocol was
devised whereby subsequent to the three doses of saline or three
increasing doses of CMF-019 or [Pyr1]apelin-13 a fourth dose
comprising of [Pyr1]apelin-13 50 nmol was administered to all
saline, CMF-19 and [Pyr1]apelin-13 treated animals. These fourth
doses were compared to assess whether there was any
desensitization of the response as a consequence of the
previous doses of CMF-019 or [Pyr1]apelin-13 administered.
Although this study was limited by the number of animals
that could be used and a high variance in the 50 nmol [Pyr1]
apelin-13 responses, there is a clear trend across the parameters.
FIGURE 7 |Cardiovascular responses to [Pyr1]apelin-13 at 50 nmol administered as a fourth dose following three successive doses of either saline pH9, CMF-019
or [Pyr1]apelin-13 in vivo. Graphs show changes in arterial pressure (A), contractility (dP/dtMAX) (B), left ventricular systolic pressure (LVSP; C), stroke volume (SV; D),
cardiac output (CO; E), heart rate (HR; F) and relaxation (dP/dtMIN) (G) to 50 nmol [Pyr
1]apelin-13 in anaesthetized male Sprague-Dawley rats previously administered
with three doses of either saline (C, n  4) or CMF-019 potassium salt (■, n  8) or Pyr1]apelin-13 (▲, n  5). The response to [Pyr1]apelin-13 after CMF-019 or [Pyr1]
apelin-13 was compared by a Student’s t-test to that after saline control (***p < 0.001).
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There was very little difference in responses to 50 nmol [Pyr1]
apelin-13 in any parameter when they had received saline or
CMF-019 for the first three doses. In contrast the increase in
contractility produced by 50 nM [Pyr1]apelin-13 following saline
was significantly attenuated following the three doses of [Pyr1]
apelin-13 and there was a trend for other parameters to be
blunted. A limitation of this study is that the maximum
response induced by CMF-019 was lower than that to [Pyr1]
apelin-13 however overall the data suggested that CMF-019 did
not desensitize the apelin receptor in vivo.
CONCLUSION
The identification of CMF-019, the first G protein biased small
molecule apelin agonist, represents an advance in the
development of small molecule apelin agonists for use as
experimental tool compounds for in vitro and in vivo study.
This is confirmed by the fact it is already commercially available
and methods to improve the synthesis of the molecule have been
attempted (Trifonov et al., 2018). Furthermore, it has potential as
a starting point or stimulus for the development of newer biased
small molecule therapeutics at the apelin receptor with improved
pharmacokinetic profiles (Narayanan et al., 2020).
In this study, we have shown that CMF-019 is able to rescue
endothelial cell apoptosis that has been shown to be a driver of
early PAH pathogenesis. Moreover, we have demonstrated that
CMF-019 is able to induce vasodilatation despite its pronounced
G protein bias, in addition to cardiac inotropy. Overall, this study
supports further investigation of novel G protein biased apelin
agonists such as CMF-019 but with improved pharmacokinetics
as potential therapeutics in PAH.
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